StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation
Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an investigational adjunctive therapy designed to extend AF treatment beyond the hospital and into the home. LOS ANGELES, Oct. 29, 2026 /PRNewswire/ -- StimCardio, a clinical-stage...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.